Genotype-informed docosahexaenoic acid dosing based on the FADS Indel to reduce preterm and prolonged gestation: A secondary analysis of the ADORE randomized trial
Tailoring fish oil doses to a person's genes improved the chances of healthy pregnancy length in this analysis.
This PubMed-indexed secondary/post-hoc analysis of a randomized trial examined Genotype-informed docosahexaenoic acid dosing based on the FADS Indel to reduce preterm and prolonged gestation: A secondary analysis of the ADORE randomized trial. The abstract reports that analysis by retrospectively pairing high dose to I-carrier genotype and low dose to D/D was associated with the highest proportion of births at 37-40 weeks.
What the study was
- Study design
- Secondary/post-hoc analysis of a randomized trial
- Population
- Genotype-informed docosahexaenoic acid dosing based on the FADS Indel to reduce preterm and prolonged gestation: A secondary analysis of the ADORE randomized trial.
- Sample size
- 574
- Category
- Genomics/Precision Medicine
- Maturity
- Validated
- Journal
- PLoS medicine
Why it surfaced
Secondary/post-hoc analysis of a randomized trial with an abstract-supported finding relevant to Precision oncology and genomic medicine; scored conservatively because only the PubMed abstract was reviewed.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.